Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 837 Cr.
- Current Price ₹ 710
- High / Low ₹ 1,022 / 580
- Stock P/E 33.9
- Book Value ₹ 276
- Dividend Yield 0.14 %
- ROCE 11.7 %
- ROE 8.70 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 90.7% CAGR over last 5 years
Cons
- Company has a low return on equity of 10.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 12 | 18 | 25 | 45 | 64 | 79 | 94 | |
| 12 | 18 | 21 | 34 | 43 | 53 | 64 | |
| Operating Profit | 0 | 1 | 4 | 11 | 21 | 26 | 30 |
| OPM % | 3% | 4% | 17% | 23% | 33% | 33% | 32% |
| 1 | 1 | 1 | 2 | 3 | 3 | 7 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Profit before tax | 1 | 1 | 5 | 11 | 22 | 27 | 33 |
| Tax % | 27% | 25% | 26% | 26% | 26% | 25% | 26% |
| 1 | 1 | 3 | 8 | 17 | 20 | 25 | |
| EPS in Rs | 4.29 | 9.66 | 14.33 | 16.86 | 20.97 | ||
| Dividend Payout % | 0% | 0% | 0% | 3% | 5% | 4% | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 39% |
| 3 Years: | 28% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 91% |
| 3 Years: | 43% |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 38% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 11% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 1 | 1 | 1 | 6 | 12 |
| Reserves | 2 | 3 | 6 | 18 | 152 | 236 | 314 |
| 0 | 0 | 0 | 8 | 4 | 4 | 6 | |
| 3 | 8 | 9 | 8 | 26 | 34 | 50 | |
| Total Liabilities | 5 | 11 | 16 | 35 | 183 | 280 | 382 |
| 0 | 0 | 0 | 3 | 5 | 7 | 7 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 3 | 21 | 127 | 209 | 297 |
| 5 | 11 | 12 | 11 | 51 | 64 | 77 | |
| Total Assets | 5 | 11 | 16 | 35 | 183 | 280 | 382 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 1 | -0 | 5 | 5 | 6 | 16 | 26 | |
| -1 | -0 | -5 | -15 | -47 | -12 | -26 | |
| 0 | -0 | -0 | 12 | 42 | -1 | 0 | |
| Net Cash Flow | 1 | -0 | 0 | 2 | 1 | 2 | -1 |
| Free Cash Flow | 1 | -0 | 5 | 3 | 3 | 12 | 22 |
| CFO/OP | 413% | 31% | 150% | 79% | 60% | 89% | 110% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 71 | 43 | 39 | 83 | 72 | 92 |
| Inventory Days | 23 | 36 | 47 | 5 | 25 | 22 | 25 |
| Days Payable | 68 | 164 | 139 | 60 | 108 | 53 | 60 |
| Cash Conversion Cycle | 5 | -56 | -48 | -16 | 0 | 42 | 57 |
| Working Capital Days | 19 | -20 | -39 | 1 | 132 | 177 | 241 |
| ROCE % | 46% | 92% | 69% | 25% | 13% | 12% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Number of Registered Products Count |
|
||||
| Number of Commercialized Products Count |
|||||
| Number of Countries Presence Count |
|||||
| B2C Revenue Contribution % |
|||||
| New Product Approvals Count |
|||||
| Number of Manufacturing Partners (CMOs) Count |
|||||
| Number of Ready-to-File Dossiers Count |
|||||
| Total SKUs Count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
28 May 2026 - Remus Pharmaceuticals released H2 FY26 and FY26 earnings call transcript; FY26 consolidated revenue 854 crore, PAT 46 crore.
-
Analysts/Institutional Investor Meet/Con. Call Updates
21 May 2026 - Audio recording of FY26 earnings conference call is available online.
-
Investor Presentation
21 May 2026 - Remus Pharma released investor presentation for H2-FY26 and FY26 ahead of earnings call.
-
Appointment
20 May 2026 - Sharp & Tannan Associates appointed internal auditor for FY 2026-27 on May 20, 2026.
-
Appointment
20 May 2026 - Board appointed Mr. Tapan Shah as Secretarial Auditor for FY 2026-27 on May 20, 2026.
Annual reports
Concalls
-
May 2026TranscriptPPT REC
-
Nov 2025Transcript PPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT
-
Nov 2024Transcript PPT REC
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing